ProQR Completes Patient Dosing for QR-010 Phase 1b Trial
ProQR Therapeutics N.V. announced it completed the dosing of cystic fibrosis patients in its Phase 1b clinical trial of QR-010.
ProQR Therapeutics N.V. (NASDAQ:PRQR) announced it completed the dosing of cystic fibrosis patients in its Phase 1b clinical trial of QR-010.
As quoted in the press release:
About the PQ-010-01 Phase 1b Clinical Trial
The PQ-010-001 study is a Phase 1b, 28-day, randomized, double-blind, placebo-controlled safety and tolerability trial, conducted in patients that have cystic fibrosis (CF) due to two copies of the F508del mutation (homozygotes). A total of 4 dose levels were studied: 6.25, 12.5, 25 and 50mg of QR-010 in solution per dose administered via inhalation. The study design consisted of 8 cohorts of 8 patients for a total of 64 patients. In each cohort, 6 patients received QR-010 and 2 patients received placebo.